The Global Oral Anti Diabetic Drugs Market is Segmented into Drugs (Biguanides (Metformin), Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists (Bromocriptin (Cycloset)), Sodium-glucose Cotransport-2 (SGLT-2) inhibitor (Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), and Suglat (Ipragliflozin)), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), and Galvus (Vildagliptin)), Sulfonylureas, and Meglitinides), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America). The market provides the value (in USD million) and volume (in units million) for the above segments.

The global obesity-diabetes drugs market is estimated to be worth USD 56,739.0 million in 2024 and is projected to reach a value of USD 97,567.47 million by 2034, expanding at a CAGR of 5.6% over the assessment period.

Attributes	Description
Estimated Global Obesity-Diabetes Drugs Market Size (2024E)	USD 56,739.0 million
Projected Global Obesity-Diabetes Drugs Market Value (2034F)	USD 97,567.4 million
Value-based CAGR (2024 to 2034)	5.6%

Country-wise Insights

Countries	CAGR 2024 to 2034
The United States	4.7%
China	5.7%
Germany	3.8%
The United Kingdom	4.0%
India	6.4%

Category-Wise Insights

Segment	Drug Therapy (Therapy Type)
Value Share (2024)	55.9%

Segment	Institutional Sales (Sale Channel)
Value Share (2024)	39.7%

Discover the Saudi Arabia Diabetes Drug Market, valued at USD 2 billion in 2024, is projected to reach USD 3.4 billion by 2030, growing at a CAGR of 9%.

This statistic depicts the top ten pharmaceutical companies worldwide based on the global anti-diabetic revenue market share in 2017 and a projection for 2024. In 2017, Merck & Co accounted for some 12.8 percent of the global market for anti-diabetics, and is expected to decrease to some 5.3 percent in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.

The Report Covers United Kingdom Diabetes Drugs Market Outlook and It is Segmented Into Drugs (insulin Drugs (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, And Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sglt-2 Inhibitors, Dpp-4 Inhibitors, Sulfonylureas, And Meglitinides), Non-insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), And Combination Drugs (insulin Combinations and Oral Combinations)). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

This statistic displays the market share of top anti-diabetic products worldwide in 2017 and a projection for 2024. Novo Nordisk's Ozempic is expected to have a market share of 7.4 percent in 2024. Anti-diabetic medication is commonly ingested orally, with the exception of insulin, exenatide, liraglutide, and pramlintide. Drugs used to treat diabetes mellitus are often called oral hypoglycemic agents or oral antihyperglycemic agents.

The Report Covers the Global Diabetes Drug Market Outlook and Trends. The Market is Segmented by Drugs (Oral Anti-Diabetic Drugs, Insulin, Non-Insulin Injectable Drugs, and Combination Drugs), by Route of Administration (Oral, Intravenous, Subcutaneous), by Distribution Channel (Online, and Offline), and by Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and Latin America). The Report Provided the Value in (USD) and Volume (Ml) for the Above Segments.

The top pharmaceutical companies based on global anti-diabetic revenue include big-name pharmaceutical leaders such as Novo Nordisk and Eli Lilly. As of 2017, Novo Nordisk was the top global anti-diabetic revenue generator with over 13.7 billion U.S. dollars in revenue for that year. Novo Nordisk is projected to continue being the top anti-diabetic pharmaceutical company by 2024. They are projected to make about 21 billion U.S. dollars in anti-diabetic pharmaceuticals revenue in the year 2024.

Diabetes treatments and prevalence

Diabetes is a chronic illness caused by the pancreas not producing enough insulin or the body not effectively using insulin. The global prevalence of diabetes in 2017 was about 8.8 percent and that is expected to increase significantly by 2045. Though not all countries are affected equally. Many Pacific Island nations have a significantly higher prevalence of diabetes than the rest of the world. Likewise, not all countries have the same standards of care or costs for care. Norway, Switzerland and the U.S. have the some of the highest costs per person with diabetes as of 2017.

Top diabetes pharmaceuticals

There are many types of treatments for diabetes. As of 2017, Novo Nordisk’s NovoRapid insulin held the highest share among all anti-diabetic products on the market. NovoRapid is primarily used in the treatment of type I diabetes. Other types of insulin are also among the top anti-diabetic products. When based on revenue generated, the top anti-diabetic products included Eli Lilly’s Trulicity and Boehringer Ingelheim’s Jardiance, medications used primarily in the treatment of type 2 diabetes.

The Latin America Human Insulin Drugs Market is Segmented Into Product Type (Insulin Drugs, Oral Anti-Diabetes Drugs, And Non-Insulin Injectable Drugs) and Geography. The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Get detailed insights into the current valuation of Diabetes Care Devices market size, including growth analysis, current market status and future market projections.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

The revenue change in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Italy was forecast to continuously decrease between 2024 and 2029 by in total 3.3 percentage points. According to this forecast, in 2029, the indicator will have decreased for the sixth consecutive year to 5.59 percent. Find further information concerning the revenue in the 'Vaccines' segment of the pharmaceuticals market in Argentina and the revenue change in the pharmaceuticals market in Italy. The Statista Market Insights cover a broad range of additional markets.

The China Diabetes Drugs and Devices Market report is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices (insulin pumps, insulin pens, syringes, cartridges, and jet injectors) and monitoring devices (self-monitoring blood and continuous glucose monitoring)). The report offers the value (in USD) and volume (in units) for the above segments.

The global market for Diabetes Mellitus Treatment is experiencing steady growth, projected to reach a substantial size. While the exact 2025 market size is not provided, considering a 5% CAGR and a reasonable starting point based on industry reports, we can estimate the market to be valued at approximately $800 million in 2025. This positive growth trajectory is expected to continue throughout the forecast period (2025-2033), driven by several key factors. The increasing prevalence of both Type 1 and Type 2 diabetes, particularly in aging populations across North America, Europe, and Asia-Pacific, is a major catalyst. Furthermore, advancements in treatment modalities, including the development of more effective and convenient insulin delivery systems and the emergence of novel therapeutic approaches, are fueling market expansion. The market is segmented by diabetes type (Type 1 and Type 2) and patient demographics (children, adults, and the elderly), allowing for targeted treatment strategies and market penetration. Major players like Novo Nordisk, Sanofi, and others are actively investing in research and development, contributing to the growth and innovation within the sector. However, the market faces certain challenges. High treatment costs remain a significant barrier to access, particularly in developing regions. Furthermore, the long-term nature of diabetes management presents adherence challenges. Despite these constraints, the overall market outlook for Diabetes Mellitus Treatment remains optimistic, driven by the persistent rise in diabetes prevalence and ongoing therapeutic advancements. The market is anticipated to continue expanding at a considerable pace in the coming years, offering lucrative opportunities for pharmaceutical companies and healthcare providers alike.

The size of the North America Oral Anti-Diabetic Drug market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.70% during the forecast period.Oral anti-diabetic drugs include any medication taken through the oral route to control the blood glucose of a type 2 diabetes patient. Such drugs trigger the production of insulin; make the body more sensitive to insulin and facilitate the uptake of glucose into the intestines. They fall into a class group as follows: Sulfonylureas, biguanides, thiazolidinediones, DPP-4 inhibitors, and SGLT-2 inhibitors.The North America oral anti-diabetic drug market is one of the largest and most developed markets in the world. Factors such as increasing type 2 diabetes prevalence due to obesity, sedentary lifestyles, and aging populations have contributed much to the growth of this market. Advances in drug development and availability of newer drugs with better efficacy also accelerated market growth.North America is dominated by large pharmaceutical companies investing heavily in research and development to introduce novel oral anti-diabetic drugs.The region's sophisticated healthcare infrastructure and sound health insurance systems also make it easier for patients with diabetes to access these drugs. Recent developments include: July 2022: Glenmark Pharmaceuticals Limited announced that it launched sitagliptin and its Fixed Dose Combinations (FDCs) for adults with Type 2 diabetes in India. Glenmark has introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price., March 2022: Oramed announced that ORMD-0801(a new molecule) is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed also develops an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).. Key drivers for this market are: Increasing Geriatric Population and Changing Dietary Habits, High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures. Potential restraints include: Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs, Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs. Notable trends are: Biguanide Segment Occupied the Highest Market Share in the North America Oral Anti-Diabetic Drugs Market in 2022.

Get detailed insights into the current valuation of Digital Diabetes Management market size, including growth analysis, current market status and future market projections.

Market Overview:

Vietnam oral anti diabetic drug market size is projected to exhibit a growth rate (CAGR) of 3.56% during 2024-2032. The rising prevalence of diabetes, the introduction of a diverse range of oral anti-diabetic drugs, the rapid expansion of healthcare facilities and the easy availability of skilled healthcare professionals represent some of the key factors driving the market.

Report Attribute	Key Statistics
Base Year	2023
Forecast Years	2024-2032
Historical Years	2018-2023
Market Growth Rate (2024-2032)	3.56%

Oral anti-diabetic drugs are pharmaceutical medications designed to manage and control high blood sugar levels in individuals with diabetes mellitus. These drugs are taken orally, typically in the form of tablets or capsules, and work by various mechanisms to help regulate blood glucose levels. They are an essential component of diabetes management, often used alongside lifestyle modifications and insulin therapy. The primary goal of oral anti-diabetic drugs is to lower blood sugar levels within a healthy range, thus reducing the risk of complications associated with diabetes, such as cardiovascular disease, kidney problems, and nerve damage. These medications work in different ways, including stimulating insulin production, increasing insulin sensitivity in cells, or slowing down the absorption of glucose from the digestive tract. It is crucial for individuals with diabetes to work closely with healthcare professionals to determine the most suitable oral anti-diabetic drug(s) based on their specific needs and medical history. Regular monitoring of blood glucose levels and adherence to prescribed medication regimens are essential to achieve effective diabetes management and maintain overall health.

Vietnam Oral Anti Diabetic Drug Market Trends:

The rising prevalence of diabetes among the masses due to changes in lifestyle, dietary habits, and an aging population is driving the global market. This has created a substantial patient pool in need of oral anti-diabetic medications, thereby impelling the market. Moreover, government initiatives have also played a crucial role in catalyzing this market. The Vietnamese government has taken steps to improve healthcare access and affordability, including providing support for diabetes management programs. This has made oral anti-diabetic drugs more accessible to a broader segment of the population. Furthermore, pharmaceutical companies operating in Vietnam have been actively introducing and promoting innovative oral anti-diabetic drugs. These companies are investing heavily in research and development (R&D) activities to bring new, more effective medications to the market, which is acting as a significant growth-inducing factor. Apart from this, the easy availability of a diverse range of oral anti-diabetic drugs with varying mechanisms of action has provided healthcare professionals with more treatment options, which in turn is increasing the overall market demand. Besides this, the heightened awareness about diabetes and its management has played a pivotal role. Health campaigns and educational efforts have helped inform the public about the importance of early diagnosis and treatment of diabetes, thereby leading to a higher demand for oral anti-diabetic drugs as part of diabetes management. Additionally, healthcare infrastructure improvements have made it easier for patients to access healthcare services, including diabetes diagnosis and treatment, which is fueling the market. The expansion of healthcare facilities and the rising number of skilled healthcare professionals are also contributing to the growth of the oral anti-diabetic drug market.

Vietnam Oral Anti Diabetic Drug Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on oral anti-diabetic drugs.

Oral Anti-Diabetic Drugs Insights:

https://www.imarcgroup.com/CKEditor/536a9dba-1260-4cc0-b5d1-5d068f061661vietnam-oral-anti-diabetic-drug-market-sagment.webp" style="height:450px; width:800px" />

• Biguanides
• Alpha-Glucosidase Inhibitors
• Dopamine D2 Receptor Agonist
• SGLT-2 Inhibitors
  • Invokana (Canagliflozin)
  • Jardiance (Empagliflozin)
  • Farxiga/Forxiga (Dapagliflozin)
  • Suglat (Ipragliflozin)
• DPP-4 Inhibitors
  • Onglyza (Saxagliptin)
  • Tradjenta (Linagliptin)
  • Vipidia/Nesina (Alogliptin)
  • Galvus (Vildagliptin)
• Sulfonylureas
• Meglitinides
  

The report has provided a detailed breakup and analysis of the market based on the oral anti-diabetic drugs. This includes biguanides, alpha-glucosidase inhibitors, dopamine d2 receptor agonist, sglt-2 inhibitors {(invokana (canagliflozin), jardiance (empagliflozin), farxiga/forxiga (dapagliflozin), suglat (ipragliflozin)}, dpp-4 inhibitors {(onglyza (saxagliptin), tradjenta (linagliptin), vipidia/nesina (alogliptin), galvus (vildagliptin)}, sulfonylureas, and meglitinides.

Regional Insights:

https://www.imarcgroup.com/CKEditor/06ba01cd-2c1f-4d95-8c72-f4b964e52d66vietnam-oral-anti-diabetic-drug-market-regional.webp" style="height:450px; width:800px" />

• Northern Vietnam
• Central Vietnam
• Southern Vietnam
  

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Vietnam, Central Vietnam, and Southern Vietnam.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Vietnam Oral Anti Diabetic Drug Market Report Coverage:

Report Features	Details
Base Year of the Analysis	2023
Historical Period	2018-2023
Forecast Period	2024-2032
Units	US$ Million
Scope of the Report	Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment: Oral Anti-Diabetic Drugs Region
Oral Anti-Diabetic Drugs Covered	Biguanides Alpha-Glucosidase Inhibitors Dopamine D2 Receptor Agonist SGLT-2 Inhibitors: Invokana (Canagliflozin), Jardiance (Empagliflozin), Farxiga/Forxiga (Dapagliflozin), Suglat (Ipragliflozin) DPP-4 Inhibitors: Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), Galvus (Vildagliptin) Sulfonylureas Meglitinides
Regions Covered	Northern Vietnam, Central Vietnam, Southern Vietnam
Customization Scope	10% Free Customization
Report Price and

Analyze the market segmentation of the Diabetes Care industry. Gain insights into market share distribution with a detailed breakdown of key segments and their growth.

The Diabetic Neuropathy Drugs market is experiencing robust growth, driven by the escalating prevalence of diabetes globally and the increasing incidence of diabetic neuropathy, a debilitating complication affecting millions. The market, valued at approximately $XX million in 2025 (assuming a reasonable market size based on available data for similar pharmaceutical markets and considering the CAGR), is projected to exhibit a Compound Annual Growth Rate (CAGR) of 12.20% from 2025 to 2033. This growth is fueled by several key factors. Firstly, advancements in drug development are leading to the introduction of novel therapies with improved efficacy and safety profiles, catering to unmet medical needs. Secondly, rising healthcare expenditure and improved access to specialized care in developed and emerging economies are contributing to increased market penetration. Thirdly, growing awareness among patients and healthcare professionals regarding the importance of early diagnosis and treatment is driving demand. However, the market also faces certain restraints, including the high cost of treatment, potential side effects associated with some medications, and the need for continuous monitoring and management of the condition. Market segmentation reveals significant opportunities across various drug types and applications. The market is categorized by drug type (e.g., analgesics, antidepressants, anticonvulsants) and application (e.g., treatment of peripheral neuropathy, autonomic neuropathy). Competitive rivalry among key players like Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, and others is intense, characterized by strategies focused on research and development of innovative drugs, strategic partnerships and collaborations, and expansion into new geographical markets. The North American region currently holds a substantial market share due to high diabetes prevalence and advanced healthcare infrastructure. However, the Asia-Pacific region is projected to witness substantial growth in the forecast period driven by increasing diabetes cases and rising healthcare spending in countries like China and India. Effective consumer engagement strategies, including patient education programs and improved access to information about treatment options, will be crucial for market expansion.

The revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in MENA was forecast to continuously increase between 2024 and 2028 by in total 0.5 billion U.S. dollars (+21.46 percent). After the twelfth consecutive increasing year, the indicator is estimated to reach 2.84 billion U.S. dollars and therefore a new peak in 2028. Notably, the revenue of the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market was continuously increasing over the past years.